Search

Abstract Grafting is a technique that involves attaching a rootstock to the aerial part of another genotype or species (scion), leading to improved crop performance and sustainable growth. The ability to tolerate abiotic stresses depends on cell membrane stability, a reduction in electrolyte leakage, and the species of scion and rootstock chosen. This external mechanism, grafting, serves as a beneficial tool in influencing crop performance by combining nutrient uptake and translocation to shoots, promoting sustainable plant growth, and enhancing the potential yield of both fruit and vegetable crops. Grafting helps to enhance crop production and improve the capacity of plants to utilize water when undergoing abiotic stress, particularly in genotypes that produce high yields upon rootstocks that are capable of decreasing the impact of drought stress on the shoot. The rootstock plays a pivotal role in establishing a grafted plant by forming a union between the graft and the rootstock. This process is characterized by its integrative, reciprocal nature, enabling plants to tolerate abiotic stress conditions. Grafting has been shown to alleviate the overproduction of lipid peroxidation and reactive oxygen species in the leaves and roots and enhance drought tolerance in plants by maintaining antioxidant enzyme activities and stress‐responsive gene expression. Phytohormones, such as cytokinin, auxin, and gibberellin, play a critical role in maintaining rootstock‐scion interactions. This review unveils the role of grafting in mitigating various environmental stressors, establishment of a robust graft junction, physiology of rootstock‐scion communication, the mechanism underlying rootstock influence, hormonal regulations and the utilization of agri‐bots in perfect healing and further cultivation of vegetable crops through grafting.

An excellent technique for producing pharmaceuticals called ''molecular farming'' enables the industrial mass production of useful recombinant proteins in genetically modified organisms. Protein-based pharmaceuticals are rising in significance because of a variety of factors, including their bioreactivity, precision, safety, and efficacy rate. Heterologous expression methods for the manufacturing of pharmaceutical products have been previously employed using yeast, bacteria, and animal cells. However, the high cost of mammalian cell system, and production, the chance for product complexity, and contamination, and the hurdles of scaling up to commercial production are the limitations of these traditional expression methods. Plants have been raised as a hopeful replacement system for the expression of biopharmaceutical products due to their potential benefits, which include low production costs, simplicity in scaling up to commercial manufacturing levels, and a lower threat of mammalian toxin contaminations and virus infections. Since plants are widely utilized as a source of therapeutic chemicals, molecular farming offers a unique way to produce molecular medicines such as recombinant antibodies, enzymes, growth factors, plasma proteins, and vaccines whose molecular basis for use in therapy is well established. Biopharming provides more economical and extensive pharmaceutical drug supplies, including vaccines for contagious diseases and pharmaceutical proteins for the treatment of conditions like heart disease and cancer. To assess its technical viability and the efficacy resulting from the adoption of molecular farming products, the following review explores the various methods and methodologies that are currently employed to create commercially valuable molecules in plant systems.